Vitiligo

STRATA Skin Sciences Expands into $300 Million Market with Exclusive Distribution Agreement in Mexico

Retrieved on: 
Monday, January 9, 2023
Vitiligo, Acne, STRATA, Skin, Psoriasis, Partnership, Strata Skin Sciences, Marketing, Acquisition, Pharmaceutical industry

“We are excited to have entered into an exclusive sales agreement with MINO Labs,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.

Key Points: 
  • “We are excited to have entered into an exclusive sales agreement with MINO Labs,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.
  • “With the addition of Mexico, STRATA has the potential to access a nearly $300 million market for acne, psoriasis, and vitiligo.
  • MINO’s 20 years of experience in the pharmaceutical industry and deep expertise in the Central and Latin American region, will allow STRATA to provide those in Mexico who suffer from skin conditions another treatment option.
  • In particular, there is a high need for acne treatments as 80%1 of the Mexican population is affected by low to severe acne.

AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo

Retrieved on: 
Monday, December 19, 2022
Melanocyte, Food, PMA, ASX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Avita Medical, Regenerative medicine, Vitiligo, FDA, Transplant, AVH, Pharmaceutical industry

The application, if approved, will expand the indication of RECELL to include the treatment of stable vitiligo.

Key Points: 
  • The application, if approved, will expand the indication of RECELL to include the treatment of stable vitiligo.
  • “We are pleased to take the next step towards expanding the clinical application of RECELL into a treatment for vitiligo,” said Jim Corbett, AVITA Medical Chief Executive Officer.
  • We anticipate a full launch of this treatment option in January 2025.”
    This PMA application includes the recently released results of the pivotal trial for vitiligo.
  • Under the program, AVITA Medical will receive prioritized review and interactive communication with the FDA throughout the premarket review phase.

Global Phototherapy Equipment Market Report 2022 to 2027: Increasing Prevalence of Neonatal Jaundice and Various Other Dermatological Ailments Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 30, 2022
Health, Health Technology, Skin, Light, Infection, Bilirubin, Serum, Neonatal jaundice, COVID-19, Jaundice, Inflammation, Acne, Rosacea, R, Wound healing, LED, Vitiligo, Psoriasis, Greg Camp, Light therapy, Prevalence, Dermatitis, Pharmaceutical industry, Medical device

The procedure comprises radiant warmers, oxygen hood, jaundice meter, transcutaneous bilirubin meter, and other fiberoptic phototherapy devices as some of the common tools.

Key Points: 
  • The procedure comprises radiant warmers, oxygen hood, jaundice meter, transcutaneous bilirubin meter, and other fiberoptic phototherapy devices as some of the common tools.
  • The global phototherapy equipment market is primarily driven by the increasing prevalence of neonatal jaundice and various other dermatological ailments, such as eczema, acne, hives, and rosacea.
  • Additionally, the introduction of intelligent LED-equipped phototherapy equipment to reduce inflammation, stimulate collagen production, and rejuvenate the skin is contributing to the market growth.
  • The publisher provides an analysis of the key trends in each sub-segment of the global phototherapy equipment market, along with forecasts at the global, regional and country level from 2022-2027.

Medical Aesthetics Global Market Report 2022: Growing Adoption of Non-Invasive and Minimally Invasive Procedures Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022
Cosmetics, Retail, Health, Other Health, Vitiligo, Cosmeceutical, Psoriasis, Patient, Injection, Smith & Nephew, Growth, Cellulite, CORI, Skin, Hospital, Beauty salon

The "Medical Aesthetics Global Market Report 2022: Ukraine-Russia War Impact" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Aesthetics Global Market Report 2022: Ukraine-Russia War Impact" report has been added to ResearchAndMarkets.com's offering.
  • The growing adoption of minimally invasive and non-invasive aesthetic procedures is expected to propel the growth of the medical aesthetics market going forward.
  • Minimally invasive procedures refer to the technique used by medical professionals to limit the size and quantity of incisions or injections.
  • There is a rise in minimally invasive and non-invasive aesthetic procedures, which are used as treatments in medical aesthetics because they are quick, minimally invasive, safe, effective, and require little downtime.

AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders

Retrieved on: 
Tuesday, December 13, 2022
Cyprus Securities and Exchange Commission, USE, Autotransplantation, Failure, ASX, Grant Thornton International, Security (finance), Food, FDA, Regenerative medicine, CDIS, Safety, Regulation of tobacco by the U.S. Food and Drug Administration, Avita Medical, Skin, Burns, Burn, Vitiligo, PMA, Independent, Annual general meeting, Contraindication, Health care, AVH, Growth, Proxy, PMDA, Chair, Patient, File, Medical device, Management, Pharmaceutical industry, Shareholder

VALENCIA, Calif. and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the results of its 2022 Annual Meeting of Stockholders, which was held virtually on December 12, 2022 (United States) (being December 13, 2022 in Australia).

Key Points: 
  • VALENCIA, Calif. and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the results of its 2022 Annual Meeting of Stockholders, which was held virtually on December 12, 2022 (United States) (being December 13, 2022 in Australia).
  • The voting results of the Annual Meeting of Stockholders for the purposes of ASX Listing Rule 3.13.2 are attached to this announcement.
  • Authorized for release by the Chief Executive Officer of AVITA Medical, Inc.
    AVITA Medical® is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration.
  • This press release was authorized by the review committee of AVITA Medical, Inc.

AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair

Retrieved on: 
Monday, December 12, 2022
USE, Administration, Autotransplantation, Communication, ASX, Food, FDA, Regenerative medicine, Safety, Soft tissue injury, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, Avita Medical, Burns, Biomedical Advanced Research and Development Authority, Burn, Trial of the century, Vitiligo, PMA, Federal, Contraindication, Therapy, Health care, AVH, Trauma, Growth, Plantar fasciitis, PMDA, Patient, Pharmaceutical industry, Medical imaging, Medical device

The supplement, if approved, will expand the indication of RECELL to include soft tissue repair.

Key Points: 
  • The supplement, if approved, will expand the indication of RECELL to include soft tissue repair.
  • “The submission is a significant milestone in our effort to expand the label of RECELL into the soft tissue repair market opportunity,” said Jim Corbett, AVITA Medical Chief Executive Officer.
  • The RECELL System earned FDA Breakthrough Device designation for its proposed soft tissue repair indication.
  • Under the program, AVITA Medical will receive prioritized review and interactive communication with the FDA throughout the premarket review phase.

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform

Retrieved on: 
Wednesday, December 7, 2022
Physician, University, Intellectual property, United, Clinical trial, Failure, Disclosure, Regulation, Regulation Fair Disclosure, Vitiligo, Knowledge, GB, Contagious disease, Research, Patent, Therapy, Biomarker, COVID-19, Patient, BET, Pharmaceutical industry

This granted patent covers the compound in VYNE’s VYN201 program and has a 20-year term that will expire in April 2040.

Key Points: 
  • This granted patent covers the compound in VYNE’s VYN201 program and has a 20-year term that will expire in April 2040.
  • WO 2020/216779, which was filed nationally in multiple jurisdictions, and is exclusively licensed to Tay Therapeutics Limited and sublicensed to VYNE.
  • This patent is the first of the national filed applications to be granted in connection with VYNE’s bromodomain and extra-terminal domain (“BET”) inhibitor program.
  • We look forward to obtaining additional patents in other jurisdictions as we progress our BET inhibitor programs,” said David Domzalski, President and Chief Executive Officer of VYNE.

CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient

Retrieved on: 
Tuesday, December 6, 2022
Cream, Janus, Woman, JAK, Sclerotherapy, Quality of life, AD, Incidence, Partnership, Atopic dermatitis, Heredity, Autoimmune disease, Marketing, FDA, Safety, Vitiligo, CMS, Skin, Tablet, Dermatology, PD-1, Neck, TCS, Face, Plasma protein binding, Territory, Conditional sentence, Patient, Report, Alopecia areata, Prejudice, Varicose veins, Disease, Ruxolitinib, Patent, FGFR1, Janus kinase 1, Week, TCI, Pharmaceutical industry, Fine chemical, Lancet, Incyte, Novartis, Lilly

Ruxolitinib Cream is the only topical JAK inhibitor and the first vitiligo repigmentation drug approved by the U.S. FDA.

Key Points: 
  • Ruxolitinib Cream is the only topical JAK inhibitor and the first vitiligo repigmentation drug approved by the U.S. FDA.
  • Through this transaction, CMS once again brings a novel treatment option for patients with unmet medical needs.
  • The product was approved by the FDA in July 2022 for the topical non-segmental vitiligo patients.
  • In July this year, Ruxolitinib Cream became the first and only drug approved by the U.S. FDA for vitiligo patients repigmentation.

Medical Aesthetics Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Monday, December 12, 2022
Quanta, Eclipse, Therapy, AbbVie, Cellulite, Psoriasis, Johnson & Johnson, Comprehensive Technologies International, Inc. v. Software Artisans, Inc., Moles, Hospital, Edel SE & Co. KGaA, Injection, Vitiligo, Smith & Nephew, Acne, COVID-19, Patient, Growth, CORI, Skin, Acquisition, Organization, 3D printing, Dentistry, Medical imaging, Crown

The global medical aesthetics market is expected to grow from $8.67 billion in 2021 to $9.82 billion in 2022 at a compound annual growth rate (CAGR) of 13.3%.

Key Points: 
  • The global medical aesthetics market is expected to grow from $8.67 billion in 2021 to $9.82 billion in 2022 at a compound annual growth rate (CAGR) of 13.3%.
  • The regions covered in this medical aesthetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
  • The countries covered in the medical aesthetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
  • The medical aesthetics market research report is one of a series of new reports that provides medical aesthetics market statistics, including medical aesthetics industry global market size, regional shares, competitors with a medical aesthetics market share, detailed medical aesthetics market segments, market trends and opportunities, and any further data you may need to thrive in the medical aesthetics industry.

Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia

Retrieved on: 
Friday, December 2, 2022
Health, Other Health, Managed Care, General Health, Pharmaceutical, Biotechnology, Autoimmunity, Beauty, Knowledge, Inflammation, Azathioprine, Lichen planus, COVID-19, Safety, Central nervous system, Pediatrics, CMS, Ciclosporin, Atopic dermatitis, Research, Lichen, HKEX, Therapy, JAK, Ophthalmology, Hidradenitis suppurativa, Collaboration, Marketing, Security (finance), Patient, Disease, Gastroenterology, Disclosure, Partnership, MAA, AD, Annual report, Vitiligo, Pharmaceutical industry, Vaccine, Fine chemical, Cosmetics, Incyte, Dermatology

To date, we have successfully launched ruxolitinib cream (Opzelura) in atopic dermatitis and vitiligo in the United States, to help address these challenges.

Key Points: 
  • To date, we have successfully launched ruxolitinib cream (Opzelura) in atopic dermatitis and vitiligo in the United States, to help address these challenges.
  • In partnership with CMS, we believe that, if approved, ruxolitinib cream will be an innovative therapeutic option poised to also help patients and healthcare providers in Greater China.
  • We are very honored to partner with Incyte on ruxolitinib cream in Greater China and Southeast Asia.
  • Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura.